Seal Rock Therapeutics is a clinical stage biotechnology company developing first-in-class treatments for multiple diseases with no available therapies. Our discovery and development efforts are focused on small-molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein, that when activated under a variety of stressful conditions, can cause organ injury, fibrosis and inflammation. 

Seal Rock's lead clinical program is SRT-015, a phase 2-ready ASK1 inhibitor given orally for treatment of liver diseases such as alcoholic hepatitis, liver failure, and non-alcoholic steatohepatitis. SRT-015, administered topically or via injection, is in preclinical development for Parkinson's disease, amyotrophic lateral sclerosis, severe skin diseases, vision loss due to diabetes or glaucoma, and hearing loss. Additional ASK1 inhibitors are under development for oral administration to treat these and other conditions. Our mission is to develop an ASK1 inhibitor tailored to the needs of every patient with these diseases.

Targeting critical mechanisms of organ injury, inflammation, and fibrosis caused by genetic, environmental, metabolic and age-related factors.

Pipette Inserted Into Test Tube
SRT Pipeline 07.25.2022 front page.png


Seal Rock Therapeutics is developing treatments for a broad range of diseases with high unmet need resultant of the activation of ASK1 (apoptosis signal-regulating kinase 1)  proteins under stressful conditions which can then cause organ injury, fibrosis and inflammation. Disease indications include but are not limited to the areas of the Central Nervous System, Heart, and Liver. Please view our Pipeline page for more information. 

EM 1.png


SRT-015 is an internally developed, next-generation ASK1 inhibitor. It has been optimized to overcome safety liabilities of first-generation ASK1 inhibitors that led to subtherapeutic dosing and subsequent lack of efficacy.


In Phase 1 clinical trials, SRT-015 demonstrated an excellent safety profile in heathy subjects and achieved plasma levels above efficacious concentrations observed in its preclinical studies. 



Seal Rock’s founders and management have held scientific and leadership roles in public and private biotech and pharma companies. They have been involved in the discovery and development of numerous FDA-approved drugs.  


Seal Rock's scientific advisers are internationally recognized experts in liver diseases and other strategic indications for clinical development of SRT-015.